{'fraction_non_alphanumeric': 0.01912928759894459, 'fraction_numerical': 0.005936675461741424, 'mean_word_length': 5.538793103448276, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MULTIPLE BILATERAL RETINAL BREAKS AS A LONG-TERM COMPLICATION OF RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB

An 11-year-old girl developed multiple bilateral retinal breaks in areas of vitreous condensation many years after treatment for retinopathy of prematurity with intravitreal bevacizumab shortly after birth. Retinal breaks were treated with laser as prophylaxis for retinal detachment. The long-term effects of intravitreal anti–vascular endothelial growth factor for retinopathy of prematurity are not well understood or documented. Purpose: To report the occurrence of multiple bilateral retinal breaks 11 years after bevacizumab treatment for retinopathy of prematurity (ROP). Methods: A case report. Results: An 11-year-old girl developed multiple bilateral retinal breaks in areas of vitreous condensation 11 years after treatment for ROP with intravitreal bevacizumab at 4 months of age. The retinal breaks were treated with laser retinopexy as prophylaxis for retinal detachment. Discussion: Patients with a history of ROP have a lifelong increased risk of retinal tears, and the long-term effects of intravitreal anti–vascular endothelial growth factor therapy for ROP are not well understood or documented. It is unknown whether there are differences in the rates of long-term ocular complications of ROP after anti–vascular endothelial growth factor versus laser treatment of ROP. Studies are needed to compare the long-term benefits and risks associated with both approaches.